A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High-Dose Inhaled Corticosteroid plus Long-acting ß2 Ag

Project: Research project

Project Details

StatusFinished
Effective start/end date10/19/18 → 10/18/20

Funding

  • AstraZeneca LP: $8,205.00